FDA Prophylactic device Changes

This capability is part of an ongoing CME/CE drive to provide substance on labeling changes reported by the FDA. Activities of this world will be posted on Medscape on a weekly ground.

October 31, 2007 — The US Food and Drug Presidential term (FDA) has approved tadalafil soft recommendation  revisions to advise of contraindications to norethindrone ethanoate therapy; drug interactions between nelfinavir mesylate and phosphodiesterase type 5 (PDE5) inhibitors; and olsalazine sodium drug interactions with heparin products, 6-mercaptopurine, and thioguanine.Norethindrone Rayon (Aygestin) Contraindicated in Cardiovascular Disorders and Venous Thromboembolism.

On July 5, the FDA approved refuge labeling revisions for norethindrone acetate rayon tablets (Aygestin; Duramed Pharmaceuticals, Inc) to reflect additional contraindications for use.
This is a part of article FDA Prophylactic device Changes Taken from "Atrovent - Ipratropium Articles Archive" Information Blog